Search results
Calliditas Therapeutics stock target lifted on strong sales By Investing.com
Investing.com· 2 days agoOn Thursday, Jefferies, a global investment banking firm, raised the stock price target for...
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
FOX 16 Little Rock· 5 days agoKS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A ...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
FOX 4 Kansas City· 2 days agoPhase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium...
Octapharma USA Appoints New VP of Commercial Marketing & Development
New Jersey Business Magazine· 6 days agoOctapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as vice president of...
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Morningstar· 1 day agoZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the ...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 2 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks· 3 days agoFree Report) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead pipeline candidate, Descartes-08, for the treatment ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoThe study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant ...
Q1 2024 Biomx Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 days agoIn January this year, we were granted Orphan Drug Designation by the FDA for BX004. More recently, in April, we presented positive safety ...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia...
Benzinga· 2 days agoKazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum ...